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1. Introduction 
After the complete description of the human genome (approximately 3x109 bases) the best 
estimates of protein-coding genes account for about 30,000 to 40,000 genes representing 
approximately 1% of the genome. A significantly remainder fraction of the genome is 
transcribed into RNAs that do not code for proteins which are classified as non-coding 
RNAs (ncRNAs) (Wright et al., 2001). These ncRNAs were unnoticed in the genome until 
recent improvements in high-throughput technology for gene expression assays led to the 
discovery that most human transcriptional units are ncRNAs.  These ncRNAs have been 
segregated into two main classes; long and small non-coding RNAs. Over the last almost 
two decades, the family of small ncRNAs (i.e. microRNAs, siRNAs and piRNAs) has grown 
in number and relevance and emerged as new key regulators of gene expression. These 
small ncRNAs, which are ~19–32 nucleotides (nt) in length, act as sequence-specific triggers 
for mRNA degradation, translation repression, heterochromatin formation and genome 
stability affecting biological functions either by posttranscriptional silencing or stimulating 
transcript degradation. The most well known small ncRNAs are the microRNAs (miRNAs). 
To date, more than 1500 human miRNAs genes have been annotated. They are organized as 
mono- or policystronic transcriptional units in the genome located either in intergenic 
regions or within introns and exons of non-coding as well as coding transcription units 
(miRBase, release 18: November 2011). 
1.1 Biogenesis and function of microRNAs 
The defining features of these small silencing RNAs are, in addition to their short size, their 
association with members of the Argonaute family of proteins, which guide them to their 
regulatory targets. Biogenesis and effector functions of miRNAs require several complex 
steps (Figure 1). Most miRNAs are transcribed by the RNA Polymerase II as long primary 
transcripts (pri-miRNAs) with a 5’m7G cap and a 3’ poly-A tail. In humans, they are 
subsequently cleaved in the nucleus by an RNase III endonuclease, Drosha, assisted by a 
dsRNA-binding protein (DGCR8) to produce a stem-loop precursor of ≈ 70 nt in length (pre-
miRNA). Pre-miRNAs are translocated to the cytoplasm by the Exportin-5/Ran complex 
and further processed by the cytoplasmic RNase III, Dicer, yielding ≈ 22-nt duplexes. 
Several dsRNA-binding accessory proteins assist human Dicer enabling both RNA 
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unwinding and loading onto effector complexes containing members of the Argonaute 
family of proteins as key components (Chu & Rana, 2007). This complex (miRNA-induced 
silencing complex or miRISC) is loaded with the mature miRNA while the complementary 
‘‘passenger’’ strand is degraded.  
 
 
Fig. 1. miRNA biogenesis and effector pathways.  
MicroRNAs are initially transcribed by RNA polymerase II as a primary (pri)-miRNA in the 
nucleus. Binding of the pri-miRNA to DGCR8 and Drosha results in the processing of the 
pri-miRNA to a 70 nt precursor miRNA (pre-miRNA). This complex is then transported to 
the cytoplasm by a complex consisting mainly of exportin-5. In the cytoplasm, a pre-miRNA 
processing complex containing a RNase III endonuclease (Dicer) at its core is formed 
cleaving the pre-miRNA to a double stranded of ≈22 nt miRNA molecule. The miRNA is 
then separated into two single-stranded molecules; the antisense strand is incorporated in 
the RNA-induced silencing complex (RISC) through its interaction with Argonaute (AGO) 
proteins while the other strand is degraded. The mature miRNA is then transported to 
either the 3′ or 5′ untranslated region of the target mRNA (UTR) for mRNA degradation of 
inhibition of translation. As a parallel pathway, the loaded RISC is linked to the Multi-
vesicular bodies (MVB) and could be secreted to the extracellular medium an endocytosed 
by other cells. A significant fraction of miRNAs are secreted as ribonucleoprotein 
complexes. 
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This loaded complex is the effector responsible for the gene silencing of the mRNA target. 
Post-transcriptional gene silencing mediated by miRNAs involves their binding by partial or 
full complementarity to specific regions or binding sites on untranslated regions (UTRs) of 
target mRNAs. The commonly accepted mechanism of miRNA targeting in animals involves 
an interaction between the 5'-end of the miRNA called the “seed region” (about 7 nts) and 
the 3' untranslated region (3'-UTR) of the mRNA. This binding induces either translation 
inhibition or cleavage of target mRNAs. 
1.2 Expression patterns of microRNAs 
Numerous miRNAs exhibit characteristic expression patterns that could serve as a 
fingerprint of a particular tissue, cell type, biological state, etc. Some miRNAs are 
differentially expressed in developmental stages, like the first family members, lin-4 and let-
7 in C. elegans. For this reason, they were called at the beginnings stRNA (small temporal 
RNA) because they are expressed in specific temporal phases of development and regulate 
the correct developmental timing. In mammalian cells, a miRNA expression pattern can 
usually be related to its possible role. Analogous to mRNA expression, miRNA expression is 
determined by intrinsic cellular factors as well as diverse environmental variables. The 
study and characterization of miRNAs was delayed several years due to their small size. 
However, the recent development of small RNA-adapted cloning, hybridization 
technologies and sequencing protocols allowed the use of high-throughput sequencing, 
microarrays and real time PCRs to characterize small RNAs in various genomics studies. 
Taken as a whole these technical improvements are expected to greatly extend the collection 
of miRNAs in a variety of biological systems. 
1.3 MicroRNAs as key regulators of gene expression 
It has become clear that miRNAs confer a novel layer of post-transcriptional regulation 
through fine-tuning gene expression, which is widely used in plants and animals. They are 
estimated to comprise 1%–5% of animal genes making them one of the most abundant classes 
of gene expression regulators. An increasing body of experimental data and bioinformatics 
prediction of miRNA targets revealed that miRNAs are expected to regulate more than 30% of 
protein coding genes (Croce, 2009). Most genes involved in basic processes common to all cells 
are under selective pressure to avoid miRNA-mediated regulation (“antitargets”). In contrast,  
many genes involved in developmental processes, cell proliferation,  apoptosis,  metabolism, 
cell differentiation, and morphogenesis (“targets”) are enriched in miRNA binding sites by 
changes in 3’ UTR (and more recent discovered also in 5’ UTR)  length and density during 
evolution (Farazi et al., 2011). These data induced many authors to speculate about a putative 
role of miRNAs in cancer and other human pathologies.  
1.4 MicroRNAs as new actors in cancer biology 
Nowadays, it is widely accepted that miRNAs could promote or suppress malignant 
processes in a similar manner to classical oncogenes and tumor suppressors. In the first case, 
miRNAs targeting mRNAs encoding for proteins that promote tumor initiation and 
progression are classified as tumor suppressor miRNAs. Thus, the loss of function of a 
tumor suppressor miRNA by genomic deletion, mutation, epigenetic silencing, and/or 
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miRNA processing alterations ultimately leads to an inappropriate increase in levels of the 
respective mRNA target, which in turns initiate or contribute to the malignant 
transformation. On the other hand miRNAs are classified as oncogenes when their target 
mRNAs code for tumor suppressor proteins. Overexpression or amplification of these 
miRNAs is followed by down-modulation of the target tumor suppressor protein, which 
ultimately initiates or contributes to the malignant transformation (Rovira et al., 2010). 
The levels of miRNAs usually are precisely controlled in the cells to guarantee a correct cell 
life cycle, function and differentiation. It was commonly observed that aberrant expression 
of miRNAs was associated to malignant transformation. The first description of a miRNA 
associated to cancer was reported in CLL by Calin et al (Calin et al., 2002). It is known that 
the most frequent chromosomal alteration, identified in more than 50% of patients suffering 
from B-cell Chronic Lymphocytic Leukemia, is a deletion of chromosome 13q14 that 
associated with longer survival. Deletions at 11q and 17p are also typical, although much 
less frequent, and correlate with up-regulation of the zeta-chain–associated protein kinase 
70kDa (ZAP70) and a shorter overall survival. These findings led to extensive efforts to 
define a putative tumor suppressor gene or genes at the 13q14 locus. No plausible protein- 
encoding candidate was identified into this region. A perceptive change in the strategy for 
possible regulatory elements along this region unearthed the existence of two novel 
miRNAs; miR-15a and miR-16-1 (Calin et al., 2002). This was the first indication that 
miRNAs could function as tumor suppressors showing frequent deletions or down-
modulation of miR-15a/16-1 in patients suffering from CLL, and the first link between 
miRNAs and cancer. A second report from this lab showed that about 50 % of annotated 
human miRNAs are located in “fragile sites” of the genome frequently associated with 
cancer (Calin et al., 2004b). Further studies found that these related miRNAs have as target 
the mRNA encoding the antiapoptotic protein B-cell CLL/lymphoma 2 (BCL2), the up-
regulation of which is critical for CLL cell survival (Cimmino et al., 2005). Importantly, the 
direct interaction of miR-15/miR-16 with BCL2 transcripts delayed protein translation, 
induced apoptosis, and reinforced the role of miRNAs as part of a new class of tumor 
suppressor genes. 
2. MicroRNAs reported in the initiation and progresion of CLL 
The implication of miR-15a/16-1 in CLL patients described by Calin et al. and other 
fascinating results,  led to Corney et al. (Corney et al., 2007) to explore the potential 
influence of the well known tumor protein p53 (TP53) on miRNA regulation. This work 
revealed that TP53 directly activates the expression of the miR-34b/miR-34c cluster situated 
at 11q, which is proximal to the region deleted in patients with CLL who have poor 
outcomes. Along with the noticeable location of the TP53 gene at 17p, these findings were 
suggestive of a higher-order genetic connection in CLL pathogenesis. 
These findings led to a rapidly expanding series of investigations linking miRNAs to CLL. 
As a result, miRNAs are currently under evaluation as novel putative diagnostic and 
prognostic biomarkers as well as potential therapeutic targets in CLL. Consequently, 
differential miRNA signatures distinguishing between tumor and normal tissues were 
reported in leukemia and solid tumors. Several recent reports suggested a miRNA signature 
associated with diagnosis, prognosis and progression of CLL.  
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As mentioned above, Calin et al. conducted a miRNA expression profiling on a well-
annotated cohort of 94 CLL patients and identified a panel of 13 miRNAs that correlated 
with ZAP-70 expression and IgVH mutational status (Calin et al., 2005). In addition, a 
subgroup of nine miRNAs (181b, 155, 146, 24-2, 23b, 23a, 222, 221, and 29c) differentiated 
patients with a short interval to therapy from patients with a longer interval to therapy. 
These authors also identified germ line or somatic mutations in miRNA genes in 15% of CLL 
patients studied. miRNA expression in B cells from a cohort of 50 CLL patients identified 7 
upregulated miRNAs and 19 downregulated miRNAs (Calin et al., 2005). Similar to this 
previous study, the authors identified the upregulation of miR-155 and downregulation of 
miR-181a/b. Although several studies have demonstrated a correlation between 
chromosomal alterations and miRNA deregulation, these studies failed to demonstrate such 
a connection, so the questions in this topic remain to be answered. Gain of methylation was 
present in pri-miRNAs for several deregulated miRNAs, including miR-139 and miR-582. 
Thus, this suggests that epigenetic regulation is likely to have a role in altered miRNA 
expression in CLL (Nana-Sinkam & Croce, 2010). 
Interestingly, it was recently reported (Fabbri et al., 2011) that the recurring deletion hot 
spots at 13q, 11q, and 17p actually represent nodes of a complex regulatory network in CLL 
that integrates the miR-15a/miR-16-1 and miR-34b/miR-34c clusters with the tumor 
suppressor p53. These studies have lighted a comprehensive hypothesis of CLL 
pathogenesis that makes a relationship between clinical heterogeneity, complex cytogenetic 
patterns and prognostic markers. The critical interactions of anti-apoptotic factors such as 
BCL2, the p53 tumor suppressor, and the ZAP-70 tyrosine kinase, all governed by miRNAs 
that derive from the long arms of chromosomes 13 and 11, may therefore be involved in 
managing the variety of indolent or aggressive phenotypes experienced by patients with 
CLL.  
Different studies were performed to identify miRNAs profiles defining leukemic cells 
involved in CLL. Using different experimental approaches (i.e. qRT-PCR, cloning and 
microarrays of defined miRNAs) several groups reported at least 25 miRNAs that were 
differentially expressed in CLL cells versus normal cells. These miRNAs included miR-16-1, 
miR-26a, miR-206, and miR-223 (Calin et al., 2004a), miR-155, miR-21, miR-150, miR-92 and 
miR-222 (Fulci et al., 2007) and miR-181, miR-30d, let-7a and three newly reported miRNAs 
(miR-1201, miR-1202 and miR-1203) characteristics of the CLL cells (Marton et al., 2008).  
Several reports identified miRNA signatures that could act as surrogate prognostic 
biomarkers in CLL, typically by correlating expression levels of these miRNAs with 
previously established prognostic markers such as IgVH mutation status or ZAP-70 
expression (Calin et al., 2005). This signature included miR-15a, miR-195, miR-221, miR-23b, 
miR-155, miR-223, miR29a-2, miR-24-1, miR-29b-2, miR-146, miR-16-1, miR-16-2, and miR-
29c.  Some authors have also developed a quantitative RT-PCR score combining miR-29c, 
miR-223, ZAP-70 and lipoprotein lipase (Stamatopoulos et al., 2009). Over-expression of 
miR-21 and low miR-181b expression has been reported as unfavorable prognostic factors 
independent of other clinical-pathologic factors (Rossi et al., 2010).  
The rapid development of miRNA research in the past few years suggests that the roles of 
many more miRNAs in CLL have yet to be discovered. For instance, for some researchers, 
the miR-17-92 cluster is a group of miRNAs that have been studied in a wide variety of 
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cancers ((Ward et al., 2011)). This miR-17-92 cluster consists of seven miRNAs: miR-17-5p, 
miR-17-3p, miR-18, miR-19a, miR-20, miR-19b-1 and miR-92-1 transcribed from the MIR17 
Host Gene (MIR17HG) at locus 13q31.3, and members of this cluster are thought to co-
express with the proto-oncogenic transcription factor MYC (He et al., 2005). Several 
profiling studies show that expression of members of the miR-17-92 cluster is altered to 
some degree in CLL (Calin et al., 2004a; Fulci et al., 2007). Thus, advances in miRNA biology 
will likely have an increasing influence in the diagnosis, prognosis and treatment of human 
cancers, including CLL. In addition, it is discussed below the discovery of the oncogenic and 
tumor-suppressive properties of various miRNAs that come up with the possibility of 
miRNA therapy for cancer in the near future. 
2.1 The miR-15a/16-1 
The association of miR-15a/16-1 in the pathogenesis of CLL was not only the first 
implication of miRNAs in this disease, but also in cancer. The authors of this finding were 
Calin et al. who determined that miR-15a/16-1 were located in 13q14.3, and were either 
deleted or down-regulated in 68% of patients with CLL (Calin et al., 2002).  
As this chromosomal region is also deleted in other types of cancer (mantle cell lymphoma, 
multiple myeloma, DLBCL, mature T-cell lymphoma, and solid tumors) conducted several 
authors to search for the presence of tumor suppressor genes in this region. A region of 
more than 1.0 Mb was sequenced, but none of the protein genes identified were found 
implicated in the initiation or progression of CLL (Calin et al., 2005). That fact, give rise to 
some hypothesis that finally conducted authors to search for miRNAs candidates, unknown 
genes, or possibly, extremely small genes perhaps not detected by classic cloning methods 
that might reside in this region and be the real target of genomic alteration (Aqeilan et al., 
2010). On this way, a minimal deleted region (MDR) that contains two tightly linked 
miRNAs, miR-15a and mirR-16-1 was identified (Calin et al., 2002; Lagos-Quintana et al., 
2001; Migliazza et al., 2000) (Figure 2). Recent studies demonstrated that other genes located 
in the same region (deleted in leukemia gene, DLEU 2 and 7), may also function as tumor 
suppressors (Palamarchuk et al., 2010). 
In addition to chromosomal abnormalities, other mechanisms as mutation, loss of 
heterozygosis, epigenetic deregulation and defects in the miRNA biogenesis machinery, 
could also contribute to deregulation of miRNA expression (Deng et al., 2008). In this 
respect, Calin et al. demonstrated that mutations in miR-16-1 could be responsible for the 
altered expression observed in CLL patients compared with subjects without cancer 
(Aqeilan et al., 2010).  
Using bionformatic tools Cimmino et al.  (Cimmino et al., 2005) found that miR-15a and 
miR-16- sequences share complementary homology with BCL2 (B-cell CLL/lymphoma 2) 
mRNA sequence. Bcl2 is an anti-apoptotic protein that is highly expressed in CLL as in other 
types of human cancer, including leukemias, lymphomas, and carcinomas (Sanchez-Beato et 
al., 2003)  
As the BLC2 gene is overexpressed and that deletions or down-regulation of the miR-15a 
and miR-16-1 cluster have been reported to occur in the same proportion in CLL samples, it 
was proposed that miR-15a and miR-16-1 produce their anti-tumorigenic effect by targeting 
the BCL2 gene (Aqeilan et al., 2010; Cimmino et al., 2005). Its function has also been assayed 
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in vitro and in vivo. In immunocompromised nude mice, ectopic expression of miR-15a/16-1 
was found to cause dramatic suppression of tumorigenicity of MEG-01 leukemic cells 
exhibiting a loss of endogenous expression of miR-15a/ 16-1 (Calin et al., 2008) On the other 
hand, and besides the results obtained by Cimmino et al, other authors found no correlation 
between BCL2 and mir15a and miR-16-1 in cancer (Fulci et al., 2007; Hanlon et al., 2009; 
Klein et al., 2010; Linsley et al., 2007). Klein et al. (Klein & Dalla-Favera, 2010) confirmed the 
observation that the miR-15a/miR-16-1 locus controls B cell expansion by modulating 
proliferation, rather than influencing survival via regulation of BCL2 in vivo. 
Nowadays, different methodological approaches revealed that CCND1 (encoding cyclin D1) 
and WNT3A mRNAs which promote several prostate tumorigenic features, could also be 
directly affected by miR-15a/16-1 (Bonci et al., 2008), like other cancer genes such as MCL1, 
ETS1 and PDCD6IP that directly or indirectly affect cell cycle and apoptosis. 
  
Fig. 2. Localization of miR15/16 cluster on human chromosome 13.  
The 13q14 tumor suppressor locus deleted in CLL contain DLEU 2 gene where 
MIR15a/MIR16/b is located inside, between exon 4 and 5.  
2.2 The miR-34 family 
The miR-34 family has been implicated in several solid and hematological malignancies. The 
three members of the miR-34 family are encoded by two different genes: miR-34a is encoded 
by its own transcript, whereas miR-34b and miR-34c share a common primary transcript 
(Auer et al., 2007; Cole et al., 2008).  
Deregulation of the miR-34a and miR-34b/c expression by chromosomal deletion and/or 
epigenectic inactivation, presumably occurs during tumorigenesis (Hermeking, 2010).  
In the case of miR-34a, chromosomal deletion of the region in which it resides (locus 1p36) 
and epigenetic inactivation were identified in tumors.  Moreover the epigenetic inactivation 
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of miR-34a was identified in cell lines derived from some of the most common tumors and 
in primary melanoma. In addition, CpG methylation of miR-34b/c was also found in 
colorectal cancer, in oral squamous cell carcinoma and in malignant melanoma. 
In the case of CLL, the variability of the mir-34a expression observed in patients is not precisely 
associated to the just mentioned process. It was demonstrated that members of the miR-34 
family are direct p53 targets. MiR-34 genes are up-regulated by the tumor-suppressor protein 
p53, and their overexpression in turn causes senescence, apoptosis, or cell cycle arrest by 
regulating proteins such as BCL2, Cyclin D1, Cyclin E2, CDK4, and c-MYC Sirt-1, depending on 
the cell type (Corney et al., 2007; Ward et al., 2011). Further analysis effectively determined that 
miR-34a expression partially correlated with p53 status and patients with p53 mutations or 
deletions of 17p13.1, in general had lower miR-34a expression (Figure 3). However, in some 
patients decreased miR-34a was seen without p53 aberrations. These patients are homozygous 
for the single nucleotide polymorphism 309 (SNP309) in the intronic promoter of MDM2, a 
negative regulator of p53 (Asslaber et al., 2010). The down-regulation of miR-34 b/c is also 
related to a p53 inactivation and to one of the most characteristic chromosomal deletion in CLL: 
11q23.1, where the miR-34 b/c cluster is located. 
 
Fig. 3. MicroRNA-34 family regulation and targets involved in CLL. microRNA 34b (miR-
34b)/microRNA 34c (miR-34c) cluster and miR-34a are regulated by tumor suppressor 
protein p53. After DNA damage or cellular stress, p53 is activated through ATM, ARF or 
ATR pathways and transactivates target genes including the miR-34 family members. The 
mature transcripts of the activated miR-34a/b/c induce either translation inhibition or 
cleavage of the indicated RNA targets. 
2.3 The miR-29 and miR-181 in CLL 
The members of miR-29 family are arranged in two different loci; the miR-29b-1/miR-29a 
located at 7q32 and the miR-29b-2/miR-29c at 1q32.  
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Downregulation of miR-29 members have been reported in various human cancers 
including aggressive chronic lymphocytic leukemia (Garzon et al., 2009). They were 
demonstrated to have a tumor suppressor activity by targeting several oncogenes as the T-
cell leukemia/ lymphoma 1 (TCL1), the BCL2 family member MCL1, the cyclin-dependent 
kinase CDK6, and the transcriptional repressor Yy1 (Mott et al., 2007; Pekarsky et al., 2006; 
Zhao et al. 2010).).  
Fabbri et al, showed that members of the miR-29 family target also the de novo DNA 
methyltransferases (DNMTs) and can reactivate tumor suppressor genes (Fabbri et al., 2007). 
Thus, loss of miR-29 family members could cause epigenetic changes associated with CLL 
and other cancer types. 
Besides of the antitumoral activity of miR-29 overexpression by inhibition of cell 
proliferation, it was also observed that miR-29 up-regulation could also initiate acute and 
chronic leukemias in animal models. Santanam and co-workers (Santanam et al., 2010) 
developed a transgenic mice overexpressing mir-29 in mouse B cells. They reported that 
miR-29 is overexpressed in indolent CLL compared with normal B cells. In contrast, miR29 
was down-regulated in aggressive CLL. 
In addition, it was demonstrated that miR-29 inversely correlated with levels of TCL-1 in 
CLL patients. TCL-1 is a coactivator of AKT, an oncogene that inhibits apoptotic patways 
and has a critical role in the regulation of many relevant cell processes including cell 
proliferation and cell death (Santanam et al., 2010; Vasilatou et al., 2010). Taken together, 
these data led authors to hypothesize that TCL1 is mostly not expressed in indolent CLL and 
probably does not play an important role in this disease stage. Indeed, miR-29 
overexpression is not sufficient to initiate aggressive CLL. In contrast, up-regulation of TCL1 
is a critical event in the pathogenesis of the aggressive form of CLL and because miR-29 is 
down-regulated in aggressive CLL (compared with the indolent form), it contributes to the 
development of an aggressive phenotype (Santanam et al., 2010). As mir-29b, mir-181b acts 
as tumor-suppresor in aggressive CLL by targeting also the TCL-1 oncogene, there is an 
inverse correlation between TCL1 and miR-181 expression at different stages of B-cell 
development (Pekarsky et al., 2006).  
The high expression of these miRNAs is associated with expression of unmutated IgVH 
and high expression of ZAP-70, indicating an aggressive CLL phenotype (Vasilatou et al., 
2010).  
2.4 Other miRNAs potentially implicated in CLL pathogenesis 
As was previously described in this chapter, several miRNAs have been reported to be 
differently expressed in B cells from CLL compared to normal B-cells.  
The miR-155, for example, was reported overexpressed in solid tumors, including lung, 
colon, and breast cancer as well as in both acute myeloid leukemia and CLL (Garzon et al., 
2009). Frenquelli et al. (Frenquelli et al., 2010) recently showed an inverse relationship 
between miR-221/222 and p27 expression and validated p27 as a functional target for miR-
221/222 in CLL.  Fulci and co-workers (Fulci et al., 2007) found an overexpression of miR-
150, miR-223, miR-29b, and miR-29c in CLL patients with a mutated IgVH phenotype 
compared to the patients with unmutated IgVH phenotypes. 
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3. MicroRNA signatures and prognostic miRNAs in CLL 
In addition to the well known molecular factors (mutational status of IgVH, expression levels 
of ZAP-70 or β2-microglobulin and expression of CD38+)  and chromosomal abnormalities 
(11q, 13q, 17p deletions) associated to the clinical course of CLL, the molecular basis for 
these correlations was largely unknown. However, several studies identified miRNAs that 
could act as prognostic indicators in CLL, typically by correlating expression levels of these 
miRNAs with previously mentioned established prognostic indicators (Ward et al., 2011). 
One of the first works that described this relationship was published by Calin et al. in 2005. 
They described a signature of 13 miRNAs (miR- 15a, miR-195, miR-221, miR-23b, miR-155, 
miR-223, miR29a-2, miR- 24-1, miR-29b-2, miR-146, miR-16-1, miR-16-2, and miR-29c) 
differentially expressed between unmutated IgVH/ ZAP70+ and mutated IgVH/ZAP70 CLL 
patients. Further studies, using different molecular techniques, also confirmed the 
mentioned correlation (Fulci et al., 2007; Marton et al., 2008; Rossi et al., 2010; Stamatopoulos 
et al., 2009). They reveled also the implication of miR-150 and miR-181 as prognostic factors.  
It was recently reported that the deregulation of miR-181b expression can be monitored 
throughout the course of the disease, which correlate with the overexpression of 4 genes 
with great significance in CLL biology and other cancers (i.e. MCL1, TCL1, BCL2 and AID 
(Visone et al., 2009).  
An interesting link between the classical prognostic molecular and chromosomal markers of 
CLL and two groups of defined miRNAs have been recently described by Fabri et al. (Fabbri 
et al., 2011). They found that miR-15a/miR-16-1 cluster is associated with reduced 
expression levels of TP53, miR-34a, miR-34b, and miR-34c and increased protein levels of 
ZAP70. Low expression levels of ZAP70 have been found to be positively correlated with 
survival in patients with the indolent course of CLL carrying 13q deletions, and it was 
associated with increased TP53 levels and transactivation of miR-34b/ miR-34c. In this way, 
the authors found a microRNA/TP53 feedback circuitry associated with the pathogenesis 
and prognosis of CLL and revealed a new pathogenic model for human CLL. 
As mentioned above, miR-29 expression correlated with the clinical course of CLL. Low 
expression of miR-29c was associated to patients who had a poor prognosis and shorter 
treatment-free survival as well as reduced overall survival (Calin & Croce, 2009).  
Thus, advances in the identification of miRNAs as CLL biomarkers, as well as the mode of 
regulation of gene expression and the pathway in which they are involved, should provide a 
useful prognostic tool for patient stratification and more appropriated treatments. 
3.1 Circulating miRNAs as novel biomarkers in CLL 
Nowadays, after the identification of extracellular circulating microRNAs in plasma 
microvesicles or ribonucleoprotein complexes (Cortez et al., 2011; Valadi et al., 2007), they 
have become an attractive source of new nucleic acid-based biomarkers. Today miRNAs are 
considered powerful markers for early detection, prognosis, response, and recurrence 
surveillance of different cancers because they are widely involved in oncogenesis (Taylor & 
Gercel-Taylor, 2008). The diagnostic and prognostic potential of miRNAs as cancer 
biomarkers relies mainly on their high stability and resistance to storage handling. It has 
been consistently shown that serum miRNAs remain stable after being subjected to severe 
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conditions that would normally degrade most RNAs. This stability can be partially 
explained by the discovery of lipoprotein complexes, including small membrane vesicles of 
endocytic origin called exosomes or microvesicles (30-1000 nm in diameter), containing 
miRNAs, mRNAs and proteins. Exosomes can be formed through inward budding of 
endosomal membranes, giving rise to intracellular multi vesicular bodies (MVBs) that later 
fuse with the plasma membrane, releasing the exosomes to the exterior (Figure 1). In 
contrast, microvesicles are originated by outward budding from the plasma membrane. The 
utility of miRNAs as diagnostic markers will be increased because samples of human 
plasma and serum can be obtained in a less invasive manner than can tissues.  
Exosomes containing miRNAs were found in blood (Hunter et al., 2008), but also in other 
types of body fluids such as saliva and urine (Michael et al.). Importantly, exosomes 
represent a newly discovered mechanism by which donor cells can communicate and 
influence the gene expression of recipient cells. These findings were first demonstrated by 
the same study that discovered miRNAs in exosomes, in which mouse mast cell exosomes 
were added to human mast cells, leading to a subsequent detection of mouse proteins in the 
human cells (Valadi et al., 2007).   
Tumor-specific miRNAs were first discovered in the serum of patients with diffuse large B 
cell lymphoma where high levels of miR-21 correlated with improved relapse-free survival 
(Lawrie et al., 2009). In an elegant experiment in a xenograft mouse prostate cancer model, 
the presence of circulating tumor-derived miR-629 and miR-660 was confirmed in blood 
with 100% sensitivity and specificity (Mitchell et al., 2008). In addition to showing that both 
serum and plasma samples are adequate for measuring specific miRNA levels, the 
investigators reported that by measuring serum levels of miR-141, they were able to 
distinguish patients with prostate cancer from healthy subjects. Since then, over 100 studies 
have assessed the potential use of serum or plasma miRNAs as biomarkers in different types 
of cancer (Cortez et al., 2011). In a comprehensive study, miRNA-expression profiles were 
identified in the sera of patients with lung or colorectal cancer, or diabetes by extracting 
miRNA from the serum (Chen et al., 2008). Although a unique expression profile of serum 
miRNAs was identified for each cancer type, an overlap was found in the profiles of 
specimens from all diseases analyzed in the study, including diabetes. In addition, this 
study also showed that miRNA-expression profiles differed between the serum and blood 
cells of lung cancer patients, while similar miRNA-expression profiles were seen in the 
serum and blood cells of healthy controls. These findings suggest that tumor-specific 
miRNAs in serum are derived not only from circulating blood cells but also cancer cells. An 
actualized compendium of relevant circulating miRNAs with potential as biomarkers for 
cancer was recently reviewed by Cortez et al. (Cortez et al., 2011). 
Because most current approaches to cancer screening are invasive and unable to detect 
early-stage disease, it is important to determine when tumor-related circulating miRNAs 
can be detected in the bloodstream during disease development between other important 
factors. In this respect, it was recently reported that miRNAs can be also sensitive 
biomarkers for CLL, because certain extracellular miRNAs are present in CLL patient 
plasma at levels significantly different from healthy controls and from patients affected by 
other hematologic malignancies (Klein et al., 2010). Moreover, in this study the authors also 
determined that level of circulating miR-20a correlates reliably with diagnosis-to treatment 
time and miR-483–5p elevated almost six fold in plasma of CLL patients is predicted to 
target the mediators of IL-15 that induces CLL proliferation and drives CLL cell migration 
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and infiltration. Although most of the miRNA–mRNA interactions are yet to be fully 
validated, the roles of these plasma miRNAs in CLL present intriguing biological questions 
with medically significant implications (Moussay et al., 2011; Ward et al., 2011).  
4. MiRNAs as predictors of CLL responses to therapy 
4.1 Chemotherapy resistance 
In spite of the existence of effective treatments for patients suffering CLL, present 
therapeutic regimens are not totally effective and additional therapies are required. 
Recently fludarabine-refractory CLL was linked to patients with p53 deletion and low miR-
34a expression. It was previously mentioned that miR-34a is positively regulated by p53. 
Low miR-34a expression levels were statistically significantly associated with impaired 
DNA damage response, p53 mutations, and fludarabine-refractory CLL either with or 
without p53 deletion (Calin & Croce, 2009). 
In addition, patients with resistant disease exhibited increased miR-181a and decreased 
miR-29a expression as consequence of their regulation by the myelocytomatosis viral 
oncogene homolog (MYC), which is increased in patients with fludarabine-resistant disease 
(Moussay et al., 2010).  
These are the first identified miRNAs associated in the complex network of molecules 
associated to drug resistance and sensitivity in patients with CLL. 
4.2 Therapy  
According to the novel miRNAs described as biomarkers of prognosis and treatment in 
CLL, one of the most expecting use of them is the possible utility in the therapy of CLL.  
The advantage to use these molecules for therapy, compared to other RNA inhibition 
strategies, relies on the fact that they are not only tiny and simple, but also they can 
target more than one mRNA relevant for the pathway of the disease (Calin & Croce, 
2009). 
Different chemical modification as are 2′-O-methylphosphorothioate oligonucleotides, 
locked nucleic acid and miRNA sponge are currently being used to improve the blocking 
capacity and half-life of miRNA. In addition Liposome–oligonucleotide Complexes, among 
other strategies are been improved for the delivery, specificity and reduction of toxicity of 
miRNAs. 
As for miR-122, which seems to be effective for the treatment hepatitis C in ongoing clinical 
trials (Lanford et al.), the potential use of miRNAs in CLL treatment has only recently been 
envisioned and were only used in vitro. 
5. Concluding remarks 
In this chapter, we have analyzed the potential contribution of microRNAs as novel players 
and biomarkers in CLL pathogenesis.  
The role of miRNAs as key regulatory molecules that control a wide variety of fundamental 
cellular processes, such as proliferation, death, differentiation, motility, invasiveness, etc., is 
www.intechopen.com
 Contribution of microRNAs to CLL Biology and Their Potential as New Biomarkers 
 
131 
increasingly recognized in almost all fields of biological and biomedical sciences. Over the 
last years, microRNAs have emerged as new actors in cancer biology as well as new 
diagnostic biomarkers and therapeutic targets in human cancer. This review attempts to 
briefly outline our current knowledge on the abnormalities of miRNAs found to be 
associated with CLL pathogenesis and possible mechanisms underlying the roles of 
miRNAs in CLL initiation and progression and to provide a perspective insight in using 
miRNAs as new CLL biomarkers. Nowadays, microRNAs are proposed as new sensitive, 
non-invasive and inexpensive biomarkers in CLL for early stage detection, predict outcome, 
monitor treatment and screen for disease recurrence. Understanding the significance of 
microRNAs in the pathogenesis of CLL represents an important dimension in miRNA 
research as it may lead to the development of miRNA-based novel therapeutic strategies or 
diagnostic/prognostic biomarkers. Additionally, microRNAs should also afford new 
avenues for exploring innovative pathways in CLL pathogenesis.  
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